<p>Kanawha Capital Management LLC 在第二季度購買了 CVS Health Corporation (NYSE:CVS - 免費報告) 的新股份，根據該公司最近向證券交易委員會 (SEC) 提交的 13F 表格。該基金購買了 3,128 股該藥房運營商的股票，價值約為 216,000 美元。</p>
<ul>
<li>CVS Health 收益增長，股息保持強勁</li>
</ul>
<p>其他幾家對沖基金和機構投資者最近也調整了對該公司的持股。先鋒集團 (Vanguard Group Inc.) 在第一季度將其在 CVS Health 的持股增加了 0.8%。先鋒集團目前擁有 118,335,394 股該藥房運營商的股票，價值 80.17223 億美元，在此期間又增持了 969,027 股。道奇與考克斯 (Dodge &amp; Cox) 在第一季度將其在 CVS Health 的持股增加了 4.8%。道奇與考克斯目前擁有 73,459,122 股該藥房運營商的股票，價值 49.76856 億美元，在上個季度又購買了 3,353,223 股。景順 (Invesco Ltd.) 在第一季度將其在 CVS Health 的持股增加了 13.2%。景順目前擁有 20,413,853 股該藥房運營商的股票，價值 13.83039 億美元，在上個季度又購買了 2,375,764 股。普萊斯·T·羅威 (Price T Rowe Associates Inc. MD) 在第一季度將其在 CVS Health 的持股增加了 14.5%。普萊斯·T·羅威目前擁有 15,309,289 股該藥房運營商的股票，價值 10.37205 億美元，在上個季度又購買了 1,942,886 股。最後，查爾斯·施瓦布投資管理公司 (Charles Schwab Investment Management Inc.) 在第一季度將其在 CVS Health 的持股增加了 5.6%。查爾斯·施瓦布投資管理公司目前擁有 13,647,873 股該藥房運營商的股票，價值 9.24643 億美元，在上個季度又購買了 728,924 股。機構投資者和對沖基金持有該公司 80.66% 的股份。</p>
<h2>CVS Health 股價表現</h2>
<p>CVS Health 股票週五開盤價為 82.64 美元。該公司的 50 日移動平均價格為 74.00 美元，200 日移動平均價格為 68.12 美元。該公司的流動比率為 0.80，速動比率為 0.62，債務與股本比率為 0.74。該股票的市值為 1048.1 億美元，市盈率為 23.08，市盈增長比率為 0.91，貝塔值為 0.60。CVS Health Corporation 的 52 周低點為 43.56 美元，52 周高點為 82.88 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 05/12 - 05/16</li>
</ul>
<p>CVS Health (NYSE:CVS - 獲取免費報告) 最近在 7 月 31 日星期四發佈了季度財報。該藥房運營商報告每股收益 (EPS) 為 1.81 美元，超出市場共識預期的 1.46 美元，超出 0.35 美元。該公司本季度的收入為 989.2 億美元，而市場共識預期為 948.7 億美元。CVS Health 的股本回報率為 10.51%，淨利潤率為 1.17%。該公司本季度的收入較去年同期增長了 8.4%。在去年同期，該公司每股收益為 1.83 美元。CVS Health 將其 2025 財年的指引設定為 6.300-6.400 每股收益。作為一個整體，賣方分析師預計 CVS Health Corporation 本財年將發佈 5.89 每股收益。</p>
<h2>CVS Health 宣佈分紅</h2>
<p>該公司還最近披露了季度分紅，將於 11 月 3 日星期一支付。10 月 23 日星期四的股東將獲得每股 0.665 美元的分紅。這代表着每年 2.66 美元的分紅和 3.2% 的收益率。除息日為 10 月 23 日星期四。CVS Health 的派息比率目前為 74.30%。</p>
<h2>CVS Health 內部交易</h2>
<ul>
<li>現在是買入諾和諾德股票的時機嗎？</li>
</ul>
<p>在其他 CVS Health 的新聞中，董事安妮·A·芬紐肯 (Anne A. Finucane) 在 8 月 20 日星期三出售了 7,500 股該公司的股票。該股票以平均價格 71.02 美元出售，總交易額為 532,650.00 美元。出售後，該董事在公司中持有 22,156 股，價值約為 1,573,519.12 美元。此次交易使其持股減少了 25.29%。該交易已在證券交易委員會的備案中披露，相關文件可通過此鏈接訪問。內部人士持有該公司 1.22% 的股份。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些股票研究分析師最近對該股票發表了看法。扎克斯研究 (Zacks Research) 在 9 月 8 日星期一的研究報告中將 CVS Health 的股票評級從 “強買” 下調至 “持有”。羅伯特·W·貝爾德 (Robert W. Baird) 在 8 月 14 日星期四的研究報告中將 CVS Health 的股票評級從 “中性” 上調至 “跑贏大盤”，並將該公司的目標價從 71.00 美元上調至 82.00 美元。高盛集團 (Goldman Sachs Group) 在週二的研究報告中開始覆蓋 CVS Health 的股票。他們對該股票設定了 “買入” 評級和 91.00 美元的目標價。瑞穗 (Mizuho) 在 10 月 9 日星期四的研究報告中將 CVS Health 的目標價從 76.00 美元上調至 88.00 美元，並給予該股票 “跑贏大盤” 的評級。最後，Leerink Partners 在週四的研究報告中將 CVS Health 的目標價從 86.00 美元上調至 95.00 美元，並給予該股票 “跑贏大盤” 的評級。兩位分析師對該股票給予了強買評級，二十位分析師給予了買入評級，四位分析師給予了持有評級。根據 MarketBeat.com 的數據，CVS Health 的共識評級為 “適度買入”，平均目標價為 82.57 美元。</p>
<p><strong>查看我們關於 CVS Health 的最新研究報告</strong></p>
<h2>關於 CVS Health</h2>
<p>(免費報告)</p>
<p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房及消費者健康部門運營。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而非 CVS Health</li>
<li>投資者必須瞭解的場外交易（OTC）股票</li>
<li>強生的併購策略才是投資者真正需要關注的故事</li>
<li>什麼是認沽期權成交量？</li>
<li>特斯拉：一些分析師預測將下跌 30%——該恐慌了嗎？</li>
<li>股票交易：相對強弱指數（RSI）及其用途</li>
<li>對美元的對沖基金態度轉變——這三隻股票的買入信號？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 到 CVS Health 嗎？</h2>
<p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 CVS Health 並不在名單上。</p>
<p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西維斯

<p>Kanawha Capital Management LLC 在第二季度收購了 CVS Health Corporation 的新股份，購買了 3,128 股，價值約為 216,000 美元。其他機構投資者，包括先鋒集團和道奇與考克斯，也增加了他們在 CVS Health 的持股。該公司報告了強勁的季度收益，收入為 989.2 億美元，每股收益為 1.81 美元，超出預期。CVS Health 宣佈每股季度分紅為 0.665 美元，收益率為 3.2%</p>

<p>Kanawha Capital Management LLC purchased a new stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,128 shares of the pharmacy operator's stock, valued at approximately $216,000.</p>
<div class="lb-trans"><p>Kanawha Capital Management LLC 在第二季度購買了 CVS Health Corporation (NYSE:CVS - 免費報告) 的新股份，根據該公司最近向證券交易委員會 (SEC) 提交的 13F 表格。該基金購買了 3,128 股該藥房運營商的股票，價值約為 216,000 美元。</p>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>CVS Health 收益增長，股息保持強勁</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of CVS Health by 0.8% during the first quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator's stock valued at $8,017,223,000 after acquiring an additional 969,027 shares during the period. Dodge &amp; Cox raised its stake in shares of CVS Health by 4.8% during the first quarter. Dodge &amp; Cox now owns 73,459,122 shares of the pharmacy operator's stock valued at $4,976,856,000 after purchasing an additional 3,353,223 shares in the last quarter. Invesco Ltd. raised its stake in shares of CVS Health by 13.2% during the first quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator's stock valued at $1,383,039,000 after purchasing an additional 2,375,764 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of CVS Health by 14.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator's stock valued at $1,037,205,000 after purchasing an additional 1,942,886 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of CVS Health by 5.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator's stock valued at $924,643,000 after purchasing an additional 728,924 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也調整了對該公司的持股。先鋒集團 (Vanguard Group Inc.) 在第一季度將其在 CVS Health 的持股增加了 0.8%。先鋒集團目前擁有 118,335,394 股該藥房運營商的股票，價值 80.17223 億美元，在此期間又增持了 969,027 股。道奇與考克斯 (Dodge &amp; Cox) 在第一季度將其在 CVS Health 的持股增加了 4.8%。道奇與考克斯目前擁有 73,459,122 股該藥房運營商的股票，價值 49.76856 億美元，在上個季度又購買了 3,353,223 股。景順 (Invesco Ltd.) 在第一季度將其在 CVS Health 的持股增加了 13.2%。景順目前擁有 20,413,853 股該藥房運營商的股票，價值 13.83039 億美元，在上個季度又購買了 2,375,764 股。普萊斯·T·羅威 (Price T Rowe Associates Inc. MD) 在第一季度將其在 CVS Health 的持股增加了 14.5%。普萊斯·T·羅威目前擁有 15,309,289 股該藥房運營商的股票，價值 10.37205 億美元，在上個季度又購買了 1,942,886 股。最後，查爾斯·施瓦布投資管理公司 (Charles Schwab Investment Management Inc.) 在第一季度將其在 CVS Health 的持股增加了 5.6%。查爾斯·施瓦布投資管理公司目前擁有 13,647,873 股該藥房運營商的股票，價值 9.24643 億美元，在上個季度又購買了 728,924 股。機構投資者和對沖基金持有該公司 80.66% 的股份。</p>
</div><h2>CVS Health Price Performance</h2>
<div class="lb-trans"><h2>CVS Health 股價表現</h2>
</div><p>Shares of CVS Health stock opened at $82.64 on Friday. The company's 50-day moving average price is $74.00 and its two-hundred day moving average price is $68.12. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The stock has a market cap of $104.81 billion, a PE ratio of 23.08, a price-to-earnings-growth ratio of 0.91 and a beta of 0.60. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $82.88.</p>
<div class="lb-trans"><p>CVS Health 股票週五開盤價為 82.64 美元。該公司的 50 日移動平均價格為 74.00 美元，200 日移動平均價格為 68.12 美元。該公司的流動比率為 0.80，速動比率為 0.62，債務與股本比率為 0.74。該股票的市值為 1048.1 億美元，市盈率為 23.08，市盈增長比率為 0.91，貝塔值為 0.60。CVS Health Corporation 的 52 周低點為 43.56 美元，52 周高點為 82.88 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 05/12 - 05/16</li>
</ul>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. The firm had revenue of $98.92 billion for the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CVS Health (NYSE:CVS - 獲取免費報告) 最近在 7 月 31 日星期四發佈了季度財報。該藥房運營商報告每股收益 (EPS) 為 1.81 美元，超出市場共識預期的 1.46 美元，超出 0.35 美元。該公司本季度的收入為 989.2 億美元，而市場共識預期為 948.7 億美元。CVS Health 的股本回報率為 10.51%，淨利潤率為 1.17%。該公司本季度的收入較去年同期增長了 8.4%。在去年同期，該公司每股收益為 1.83 美元。CVS Health 將其 2025 財年的指引設定為 6.300-6.400 每股收益。作為一個整體，賣方分析師預計 CVS Health Corporation 本財年將發佈 5.89 每股收益。</p>
</div><h2>CVS Health Announces Dividend</h2>
<div class="lb-trans"><h2>CVS Health 宣佈分紅</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.2%. The ex-dividend date is Thursday, October 23rd. CVS Health's payout ratio is presently 74.30%.</p>
<div class="lb-trans"><p>該公司還最近披露了季度分紅，將於 11 月 3 日星期一支付。10 月 23 日星期四的股東將獲得每股 0.665 美元的分紅。這代表着每年 2.66 美元的分紅和 3.2% 的收益率。除息日為 10 月 23 日星期四。CVS Health 的派息比率目前為 74.30%。</p>
</div><h2>Insider Transactions at CVS Health</h2>
<div class="lb-trans"><h2>CVS Health 內部交易</h2>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>現在是買入諾和諾德股票的時機嗎？</li>
</ul>
</div><p>In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own 1.22% of the company's stock.</p>
<div class="lb-trans"><p>在其他 CVS Health 的新聞中，董事安妮·A·芬紐肯 (Anne A. Finucane) 在 8 月 20 日星期三出售了 7,500 股該公司的股票。該股票以平均價格 71.02 美元出售，總交易額為 532,650.00 美元。出售後，該董事在公司中持有 22,156 股，價值約為 1,573,519.12 美元。此次交易使其持股減少了 25.29%。該交易已在證券交易委員會的備案中披露，相關文件可通過此鏈接訪問。內部人士持有該公司 1.22% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of equities research analysts recently weighed in on the stock. Zacks Research cut shares of CVS Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, September 8th. Robert W. Baird upgraded shares of CVS Health from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and lifted their price objective for the company from $71.00 to $82.00 in a research note on Thursday, August 14th. The Goldman Sachs Group assumed coverage on shares of CVS Health in a research note on Tuesday. They set a &#34;buy&#34; rating and a $91.00 price objective on the stock. Mizuho boosted their price target on shares of CVS Health from $76.00 to $88.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, October 9th. Finally, Leerink Partners boosted their price target on shares of CVS Health from $86.00 to $95.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, CVS Health has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $82.57.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對該股票發表了看法。扎克斯研究 (Zacks Research) 在 9 月 8 日星期一的研究報告中將 CVS Health 的股票評級從 “強買” 下調至 “持有”。羅伯特·W·貝爾德 (Robert W. Baird) 在 8 月 14 日星期四的研究報告中將 CVS Health 的股票評級從 “中性” 上調至 “跑贏大盤”，並將該公司的目標價從 71.00 美元上調至 82.00 美元。高盛集團 (Goldman Sachs Group) 在週二的研究報告中開始覆蓋 CVS Health 的股票。他們對該股票設定了 “買入” 評級和 91.00 美元的目標價。瑞穗 (Mizuho) 在 10 月 9 日星期四的研究報告中將 CVS Health 的目標價從 76.00 美元上調至 88.00 美元，並給予該股票 “跑贏大盤” 的評級。最後，Leerink Partners 在週四的研究報告中將 CVS Health 的目標價從 86.00 美元上調至 95.00 美元，並給予該股票 “跑贏大盤” 的評級。兩位分析師對該股票給予了強買評級，二十位分析師給予了買入評級，四位分析師給予了持有評級。根據 MarketBeat.com 的數據，CVS Health 的共識評級為 “適度買入”，平均目標價為 82.57 美元。</p>
</div><p><strong>View Our Latest Research Report on CVS Health</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CVS Health 的最新研究報告</strong></p>
</div><h2>About CVS Health</h2>
<div class="lb-trans"><h2>關於 CVS Health</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p>
<div class="lb-trans"><p>CVS Health Corporation 在美國提供健康解決方案。它通過醫療保險、健康服務和藥房及消費者健康部門運營。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>What is Put Option Volume?</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 CVS Health</li>
<li>投資者必須瞭解的場外交易（OTC）股票</li>
<li>強生的併購策略才是投資者真正需要關注的故事</li>
<li>什麼是認沽期權成交量？</li>
<li>特斯拉：一些分析師預測將下跌 30%——該恐慌了嗎？</li>
<li>股票交易：相對強弱指數（RSI）及其用途</li>
<li>對美元的對沖基金態度轉變——這三隻股票的買入信號？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 到 CVS Health 嗎？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 CVS Health 並不在名單上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Kanawha Capital Management LLC 在 CVS Health Corporation 持有 21.6 萬美元的頭寸